The grapefruit effect is the well-documented rise in drug blood levels that can occur when grapefruit and related citrus — Seville orange, pomelo, and certain tangelos — inhibit intestinal CYP3A4 metabolism of paired oral medications. Because the effect can outlast the meal, spacing the fruit from the prescription does not reliably avoid the interaction for affected drugs.
What is happening at the gut wall
Furanocoumarins in grapefruit irreversibly inactivate intestinal CYP3A4 enzymes. Until the body rebuilds the enzyme pool, oral doses of paired drugs are metabolized less on first pass, and a larger share reaches the bloodstream. See first-pass metabolism for why the gut wall step matters more than the liver step for several common prescriptions.
Prescription classes most often affected
Several classes carry an explicit grapefruit warning on the label, including some statins, certain calcium-channel blockers, a subset of immunosuppressants, some psychiatric medications, and certain anticoagulants. The specific list is prescription-specific rather than class-wide, so one statin may carry the warning while another statin in the same class does not.
Why timing-based avoidance does not work
Because the affected enzymes are inactivated rather than competitively blocked, the effect outlasts the meal. A morning glass of juice followed by an evening prescription dose can still matter for some affected drugs. When the warning applies, the pharmacist or prescriber can confirm whether avoidance is required rather than relying on spacing alone.
Supplement-stack overlap
Supplements that act on the same enzyme can produce additive effects when grapefruit is also in the diet. For users assembling a routine alongside a prescription medication, the pillar overview at building your first supplement stack covers how the prescription input field changes which supplements are surfaced as candidates and which are filtered out.
Why the warning belongs in the log
The relevant content task is to record that a product, food pattern, and medication share a known warning surface. Some medications carry the warning, some do not, and a single class member can differ from its peers.
Limits of the warning list
The published list is not exhaustive and is updated as new medications come to market. A medication without an explicit warning is not proof of safety; it sometimes only reflects the absence of a specific study. The platform pulls warnings from public pharmacology references rather than generating them, so the published cadence sets the freshness of the data.
How this appears in Unfair
When a user logs a prescription that carries a published grapefruit warning, the app surfaces a one-line note on the stack record and links the relevant interaction risk prompt and pharmacist-consultation template. The note follows the prescription, not the supplement, since the fruit itself is rarely entered as a supplement.
Clinical safety note
The grapefruit list is curated from pharmacy references and is narrower than a prescriber's chart review. Prescription changes and symptom interpretation are outside the scope of a glossary entry or supplement journal.